Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms

Imagem de Miniatura
Arquivos
art_LEITE_Antimicrobial_Combinations_against_PanResistant_Acinetobacter_baumannii_Isolates_with_2016.PDF (577.15 KB)
Citações na Scopus
66
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
Citação
PLOS ONE, v.11, n.3, article ID e0151270, 16p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The study investigated the effect of antibiotic combinations against 20 clinical isolates of A. baumannii (seven colistin-resistant and 13 colistin-susceptible) with different resistance mechanisms. Clinical data, treatment, and patient mortality were evaluated. The following methods were used: MIC, PCRs, and outer membrane protein (OMP) analysis. Synergy was investigated using the checkerboard and time-kill methods. Clonality was evaluated by PFGE. Based on clonality, the whole genome sequence of six A. baumannii isolates was analyzed. All isolates were resistant to meropenem, rifampicin, and fosfomycin. OXA-23 and OXA-143 were the most frequent carbapenemases found. Four isolates showed loss of a 43kDa OMP. The colistin-susceptible isolates belonged to different clones and showed the highest synergistic effect with fosfomycin-amikacin. Among colistin-resistant isolates, the highest synergistic effect was observed with the combinations of colistin-rifampicin followed by colistin-vancomycin. All colistin-resistant isolates harbored bla(OXA-23-like) and belonged to CC113. Clinical and demographic data were available for 18 of 20 patients. Fourteen received treatment and eight patients died during treatment. The most frequent site of infection was the blood in 13 of 14 patients. Seven patients received vancomycin plus an active drug against A. baumannii; however, mortality did not differ in this group. The synergistic effect was similar for colistin-susceptible isolates of distinct clonal origin presenting with the same resistance mechanism. Overall mortality and death during treatment was high, and despite the high synergism in vitro with vancomycin, death did not differ comparing the use or not of vancomycin plus an active drug against A. baumannii.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/14266
Referências
  1. Bonapace CR, 2000, DIAGN MICR INFEC DIS, V38, P43, DOI 10.1016/S0732-8893(00)00163-2
  2. Lee Y, 2012, J APPL MICROBIOL, V112, P1207, DOI 10.1111/j.1365-2672.2012.05283.x
  3. Werneck JS, 2011, J ANTIMICROB CHEMOTH, V66, P452, DOI 10.1093/jac/dkq462
  4. Lu CL, 2011, ANTIMICROB AGENTS CH, V55, P4295, DOI 10.1128/AAC.00349-11
  5. Vidaillac C, 2012, ANTIMICROB AGENTS CH, V56, P4856, DOI 10.1128/AAC.05996-11
  6. Falagas ME, 2009, INT J ANTIMICROB AG, V34, P111, DOI 10.1016/j.ijantimicag.2009.03.009
  7. Bishburg E, 2009, INT J ANTIMICROB AG, V34, P395, DOI 10.1016/j.ijantimicag.2009.06.021
  8. Koh TH, 2007, J ANTIMICROB CHEMOTH, V59, P627, DOI 10.1093/jac/dkl544
  9. Gales AC, 2006, CLIN MICROBIOL INFEC, V12, P315, DOI 10.1111/j.1469-0691.2005.01351.x
  10. Fu YQ, 2010, J ANTIMICROB CHEMOTH, V65, P644, DOI 10.1093/jac/dkq027
  11. Lu PL, 2009, J ANTIMICROB CHEMOTH, V63, P641, DOI 10.1093/jac/dkn553
  12. Higgins PG, 2009, ANTIMICROB AGENTS CH, V53, P5035, DOI 10.1128/AAC.00856-09
  13. Ramirez MS, 2013, CURR MICROBIOL, V67, P9, DOI 10.1007/s00284-013-0326-5
  14. Sirijatuphat R, 2014, ANTIMICROB AGENTS CH, V58, P5598, DOI 10.1128/AAC.02435-13
  15. Biswas S, 2007, NAT STRUCT MOL BIOL, V14, P1108, DOI 10.1038/nsmb1304
  16. Lagesen K, 2007, NUCLEIC ACIDS RES, V35, P3100, DOI 10.1093/nar/gkm160
  17. Mendes RE, 2007, J CLIN MICROBIOL, V45, P544, DOI 10.1128/JCM.01728-06
  18. Aydemir H, 2013, EPIDEMIOL INFECT, V141, P1214, DOI 10.1017/S095026881200194X
  19. Coelho-Souza T, 2013, CLIN MICROBIOL INFEC, V19, pE241, DOI 10.1111/1469-0691.12145
  20. Zhang YJ, 2013, EXP THER MED, V5, P1737, DOI 10.3892/etm.2013.1039
  21. Woodford N, 2006, INT J ANTIMICROB AG, V27, P351, DOI 10.1016/j.ijantimicag.2006.01.004
  22. Grosso F, 2011, J ANTIMICROB CHEMOTH, V66, P62, DOI 10.1093/jac/dkq406
  23. Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
  24. Nigro SJ, 2012, J ANTIMICROB CHEMOTH, V67, P1342, DOI 10.1093/jac/dks037
  25. Petersen PJ, 2006, J ANTIMICROB CHEMOTH, V57, P573, DOI 10.1093/jac/dki477
  26. Stietz MS, 2013, INFECT GENET EVOL, V14, P294, DOI 10.1016/j.meegid.2012.12.020
  27. Agodi A, 2014, J HOSP INFECT, V86, P260, DOI 10.1016/j.jhin.2014.02.001
  28. Gordon NC, 2010, ANTIMICROB AGENTS CH, V54, P5316, DOI 10.1128/AAC.00922-10
  29. Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153
  30. Bonapace CR, 2002, DIAGN MICR INFEC DIS, V44, P363, DOI 10.1016/S0732-8893(02)00473-X
  31. Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
  32. Maiden MCJ, 2006, ANNU REV MICROBIOL, V60, P561, DOI 10.1146/annurev.micro.59.030804.121325
  33. Tognim MCB, 2004, INT J INFECT DIS, V8, P284, DOI 10.1016/j.ijid.2003.11.009
  34. Climaco EC, 2013, INFECT GENET EVOL, V19, P127, DOI 10.1016/j.meegid.2013.06.024
  35. Martins N, 2013, MICROB DRUG RESIST, V19, P216, DOI 10.1089/mdr.2012.0174
  36. O'Hara JA, 2013, ANTIMICROB AGENTS CH, V57, P2103, DOI 10.1128/AAC.02501-12
  37. Kim CK, 2010, DIAGN MICR INFEC DIS, V68, P432, DOI 10.1016/j.diagmicrobio.2010.07.014
  38. Carvalho KR, 2009, INT J ANTIMICROB AG, V34, P25, DOI 10.1016/j.ijantimicag.2008.12.009
  39. Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
  40. Mostachio AK, 2012, INT J ANTIMICROB AG, V39, P396, DOI 10.1016/j.ijantimicag.2012.01.021
  41. Chevreux B, 1999, GERM C BIOINF, V1999, P45
  42. Clinical and Laboratory Standard Institute, 2013, M100S19 CLSI
  43. Custovic Amer, 2014, Med Arch, V68, P402, DOI 10.5455/medarh.2014.68.402-406
  44. de Sá Cavalcanti Felipe Lira, 2013, Diagn Microbiol Infect Dis, V77, P250, DOI 10.1016/j.diagmicrobio.2013.07.022
  45. de Souza Gusatti Carolina, 2012, Braz J Microbiol, V43, P243, DOI 10.1590/S1517-838220120001000027
  46. Eliopoulos GM, 1996, LAB MED, P330
  47. European Committee on Antimicrobial Susceptibility Testing, 2013, EUR COMM ANT SUSC TE
  48. Garnacho-Montero J, 2013, CHEMOTHERAPY, V59, P225, DOI 10.1159/000356004
  49. Giamarellos-Bourboulis EJ, 2001, DIAGN MICR INFEC DIS, V40, P117, DOI 10.1016/S0732-8893(01)00258-9
  50. Kim Uh Jin, 2014, Chonnam Med J, V50, P37, DOI 10.4068/cmj.2014.50.2.37
  51. Mostachio Anna Karina, 2009, J Med Microbiol, V58, P1522, DOI 10.1099/jmm.0.011080-0
  52. Pillai S. K., 2005, ANTIMICROBIAL COMBIN
  53. Principe Luigi, 2009, Ann Clin Microbiol Antimicrob, V8, P18, DOI 10.1186/1476-0711-8-18
  54. Santimaleeworagun W, 2011, SE ASIAN J TROP MED, V42, P890
  55. Shahcheraghi F, 2011, Iran J Microbiol, V3, P68
  56. Wei W, 2015, J CHEMOTHER, DOI [10.1179/1973947815Y.0000000030, DOI 10.1179/1973947815Y.0000000030]

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/54